Intellia Therapeutics to Present at September Investor Healthcare Conferences

CAMBRIDGE, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham, Ph.D., will present at key September investor healthcare conferences, including the 2016 Wells Fargo Healthcare Conference, the Morgan Stanley Global Healthcare Conference and the Leerink Rare Disease & IO Roundtable Series.

Details of the upcoming presentations are as follows:

Wednesday, September 7th 2016 Wells Fargo Healthcare ConferenceLocation: The Westin Waterfront, BostonPresentation Time: 3:30-4:00 PM ET

Tuesday, September 13th2016 Morgan Stanley Global Healthcare ConferenceLocation: Grand Hyatt New York, New YorkPresentation Time: 5:15-5:40 PM ET

Wednesday, September 28thLeerink Rare Disease & IO Roundtable Series, 2016Location: Lotte New York Palace, New YorkPresentation Time: 2:05-2:30 PM ET

Individuals may access the presentations for each conference via live webcast on the Intellia website at www.intelliatx.com under "Events & Presentations" in the "Investor Relations" section. A replay of the webcast will be available on this site for 90 days following the live event.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.

Media Contact:

Jennifer Mound Smoter
Chief External Affairs & Communications Officer
+1 224-804-4462
[email protected]

Investor Contacts:

John Graziano
Trout Group
+1 646-378-2942
[email protected]

Chad Rubin
Trout Group
+1 646-378-2947
[email protected]

Source: Intellia Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wells Fargo Upgrades Yum! Brands (YUM) to Overweight
• Market Turns Red, But Apeing Surges Ahead: Could This 2,400% ROI Crypto Become the Best Crypto to Buy Now? 
• Crypto Price Prediction: The September 15 Vote That Could Start the Biggest Rally of 2026